<DOC>
	<DOC>NCT01030965</DOC>
	<brief_summary>The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD</brief_summary>
	<brief_title>28-day Repeat Dose Study of GSK573719</brief_title>
	<detailed_description>This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate 3 doses of GSK573719 administered once-daily over 28 days in subjects with COPD.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>A signed and dated written informed consent prior to study participation Males or females of nonchildbearing potential 40 to 80 years of age COPD diagnosis 10 packyears history or greater of cigarette smoking Postbronchodilator FEV1/FVC ratio of 0.70 or less Postbronchodilator FEV1 of 25 to 70% of predicted normal Asthma Other significant respiratory disorders besides COPD, including alpha1 deficiency Previous lung resection surgery Chest Xray or CP scan showing clinically significant abnormalities not due to COPD Use of oral steroids or antibiotics for a COPD exacerbation within 6 weeks of screening Hospitalization for COPD or pneumonia within 3 months of screening Any significant disease that would put subject at risk through study participation BMI greater than 35 Pacemaker Significantly abnormal ECG or clinical lab finding (including Hepatitis B or C) Cancer Allergy or hypersensitivity to anticholinergics or inhaler excipients Diseases that would contraindicate the use of anticholinergics Use of oral corticosteroids within 6 weeks of screening Use of longacting betaagonists within 48 hours of screening Use of tiotropium within 14 days of screening Use of theophyllines or antileukotrienes within 48 hours of screening Use of shortacting bronchodilators within 4 to 6 hours of screening Use of investigational medicines within 30 days of screening Use of high dose inhaled corticosteroids Use of longterm oxygen therapy, CPAP or NIPPV Participation in acute phase of pulmonary rehabilitation program History of alcohol or drug abuse within 2 years prior to screening History of psychiatric disease limiting validity of consent Affiliation with the investigative site Previous use of GSK573719</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Anticholinergic</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Long-acting muscarinic antagonist</keyword>
	<keyword>COPD</keyword>
</DOC>